WallStSmart

Qualcomm Incorporated (QCOM)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 6% more annual revenue ($47.35B vs $44.49B). QCOM leads profitability with a 22.3% profit margin vs 16.0%. QCOM appears more attractively valued with a PEG of 0.82. QCOM earns a higher WallStSmart Score of 71/100 (B).

QCOM

Strong Buy

71

out of 100

Grade: B

Growth: 5.3Profit: 8.5Value: 6.7Quality: 7.5
Piotroski: 4/9Altman Z: 3.17

SNY

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 6.5Value: 5.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

QCOMUndervalued (+8.0%)

Margin of Safety

+8.0%

Fair Value

$220.25

Current Price

$219.09

$1.16 discount

UndervaluedFair: $220.25Overvalued
SNYUndervalued (+25.0%)

Margin of Safety

+25.0%

Fair Value

$62.70

Current Price

$43.31

$19.39 discount

UndervaluedFair: $62.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

QCOM6 strengths · Avg: 9.5/10
Market CapQuality
$230.92B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.1%10/10

Every $100 of equity generates 36 in profit

EPS GrowthGrowth
173.0%10/10

Earnings expanding 173.0% YoY

Altman Z-ScoreHealth
3.1710/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
22.3%9/10

Keeps 22 of every $100 in revenue as profit

PEG RatioValuation
0.828/10

Growing faster than its price suggests

SNY4 strengths · Avg: 8.8/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Market CapQuality
$103.45B9/10

Large-cap with strong market position

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

Areas to Watch

QCOM2 concerns · Avg: 3.0/10
Price/BookValuation
10.2x4/10

Trading at 10.2x book value

Revenue GrowthGrowth
-3.5%2/10

Revenue declined 3.5%

SNY3 concerns · Avg: 2.3/10
Return on EquityProfitability
6.6%3/10

ROE of 6.6% — below average capital efficiency

PEG RatioValuation
3.762/10

Expensive relative to growth rate

EPS GrowthGrowth
-11.7%2/10

Earnings declined 11.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : QCOM

The strongest argument for QCOM centers on Market Cap, Return on Equity, EPS Growth. Profitability is solid with margins at 22.3% and operating margin at 22.1%. PEG of 0.82 suggests the stock is reasonably priced for its growth.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Profitability is solid with margins at 16.0% and operating margin at 20.0%.

Bear Case : QCOM

The primary concerns for QCOM are Price/Book, Revenue Growth.

Bear Case : SNY

The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

QCOM profiles as a declining stock while SNY is a mature play — different risk/reward profiles.

QCOM carries more volatility with a beta of 1.49 — expect wider price swings.

SNY is growing revenue faster at 6.0% — sustainability is the question.

QCOM generates stronger free cash flow (1.9B), providing more financial flexibility.

Bottom Line

QCOM scores higher overall (71/100 vs 51/100), backed by strong 22.3% margins. SNY offers better value entry with a 25.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Qualcomm Incorporated

TECHNOLOGY · SEMICONDUCTORS · USA

Qualcomm is an American multinational corporation headquartered in San Diego, California, and incorporated in Delaware. It creates semiconductors, software, and services related to wireless technology. It owns patents critical to the 5G, 4G, CDMA2000, TD-SCDMA and WCDMA mobile communications standards.

Visit Website →

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?